Where does Venatorx Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Venatorx Pharmaceuticals, Inc. ranks #8,506 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Venatorx Pharmaceuticals, Inc. hold?

Venatorx Pharmaceuticals, Inc. holds 38 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is Venatorx Pharmaceuticals, Inc.'s Innovation Score?

Venatorx Pharmaceuticals, Inc. has an Innovation Score of 38.8 out of 100 (top 40% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Venatorx Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Venatorx Pharmaceuticals, Inc.'s recent grant velocity is -5% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Venatorx Pharmaceuticals, Inc.'s patents?

Venatorx Pharmaceuticals, Inc.'s patents average 17.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Venatorx Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Venatorx Pharmaceuticals, Inc.

Q: What technology areas does Venatorx Pharmaceuticals, Inc. focus on?

Venatorx Pharmaceuticals, Inc.'s top technology area is C07F (Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium) with 36 patents, ranking #34 of 1,317 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 38 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07F (Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Venatorx ranks #8,506 of 49,997 tracked US assignees by granted-patent volume, with 38 patents across 7 technology areas.

#8,506
of 49,997 US assignees by volume: Top 40%
by Innovation Score (38.8/100): 17.8
avg claims per patent: -5%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8506 · US Corporation #8,506 · 38 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 38 grants
UPPER-Q #8,506/49,997
PHOTO-FINISH Torqeedo
CPC-NARROW C07F · 7 areas
INNOV-THIN 38.8/100
CLAIMS-RICH 17.8 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT -5% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Torqeedo GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Venatorx’s 38.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.7 pts (33%) Velocity 6.1 pts (16%) Breadth 9.4 pts (24%) Claim depth 10.7 pts (28%)

Qualcomm Incorporated · highest

85
Advanced Architectur… · near

39
Guangdong Jiamei… · near

39
Leo Pharma A/S · near

39
Ligand Pharmaceutica… · near

39
Venatorx Pharmaceuti… · this assignee

39
3D Lighting… · lowest

7

What this shows Venatorx's Innovation Score is 38.8/100 (top 40% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Venatorx?

Each dot is one of Venatorx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Venatorx’s own 17.8 claims/patent is ABOVE the 13.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Venatorx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Venatorx's grants concentrate

Venatorx Pharmaceuticals, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 94.7% of grants classified under C07F (Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium). Peak complete grant year is 2017 (5 grants) versus a trough of 1 in 2015. By volume, Venatorx sits between Torqeedo GmbH and Vandor Group, Inc..

Venatorx's three-year grant acceleration

Venatorx Pharmaceuticals, Inc. shows 11 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Torqeedo

38
Universite DE Fra…

38
Universite DE Lim…

38
Vdyne

38
VIA Labs

38
Vibia Lighting S…

38
VMR Products

38
Vandor Group

38
Venatorx Pharmace… ◀

38

What this shows Venatorx holds 38 patents at rank #8,505, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Venatorx

By rank, the assignees closest to #8,505 in granted patent volume.

Leaders in C07F (Acyclic)

Other assignees with the most granted patents in Venatorx's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Venatorx, neither rank-band nor same-CPC leaders (those blocks stay above). In C07F (Acyclic), Venatorx ranks #34 of 1,317 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Ligand Pharmaceuticals Incorporated 39 Advanced Architectural Products, LLC 39 Leo Pharma A/S 39 Guangdong Jiamei Ceramics Co., Ltd. 39

Venatorx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Venatorx Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	2.6%
2016	4	10.5%
2017	5	13.2%
2018	4	10.5%
2019	5	13.2%
2020	2	5.3%
2021	5	13.2%
2022	4	10.5%
2023	4	10.5%
2024	3	7.9%
2025partial year	1	2.6%

Which technologies does Venatorx Pharmaceuticals, Inc. patent most?

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 36

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 31

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 30

Y02A - Technologies FOR Adaptation TO Climate Change 15

C07D - Heterocyclic Compounds 7

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

C07C - Acyclic OR Carbocyclic Compounds 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Venatorx Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Venatorx Pharmaceuticals, Inc.'s lead technology class is C07F (Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium), 94.7% of its portfolio - see every assignee active in that class. Explore C07F
Ranked #8,506 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Venatorx Pharmaceuticals, Inc. against Torqeedo GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.